Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Woestenberg, Petra JKing, Audrey J
Van Benthem, Birgit H B
Leussink, Suzan
Van der Sande, Marianne A B
Hoebe, Christian J P A
Bogaards, Johannes A
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.Published in
J Infect Dis 2019; pii.jiz187PMID
31100134ae974a485f413a2113503eed53cd6c53
10.1093/infdis/jiz187
Scopus Count
Collections
Related articles
- Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors.
- Authors: Woestenberg PJ, King AJ, van Benthem BHB, Donken R, Leussink S, van der Klis FRM, de Melker HE, van der Sande MAB, Hoebe CJPA, Bogaards JA, Medical Microbiological Laboratories and the Public Health Services.
- Issue date: 2018 Jan 4
- No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
- Authors: Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories., Public Health Services.
- Issue date: 2017 Apr
- Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.
- Authors: Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR, CVT Vaccine Group.
- Issue date: 2013
- Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
- Authors: Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ
- Issue date: 2013 Feb 7
- Cost-effectiveness of different human papillomavirus vaccines in Singapore.
- Authors: Lee VJ, Tay SK, Teoh YL, Tok MY
- Issue date: 2011 Mar 31